Organon & Co. (OGN)
NYSE:OGN
Want to see OGN full AI Analyst Report?
OGN Stock Chart & Stats
$9.76
-$0.16(-1.02%)
At close: 4:00 PM EST
$9.76
-$0.16(-1.02%)
Day’s Range― - ―
52-Week Range$5.69 - $13.48
Previous CloseN/A
Volume728.75K
Average Volume (3M)6.16M
Market Cap
$3.53B
Enterprise Value$10.96B
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$8.57B
Price to Earnings (P/E)14.2
Beta0.96
Next Earnings
Aug 11, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend Yield4.8%
Share Statistics
EPS (TTM)0.95
Shares Outstanding262,609,440
10 Day Avg. Volume2,877,247
30 Day Avg. Volume6,157,226
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.47
Price to Sales (P/S)0.30
P/FCF Ratio3.46
Enterprise Value/Market Cap3.10
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda7.92
Forecast
1Y Price Target
$12.33Price Target Upside26.37% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)3.4
Revenue Forecast (FY)$6.13B
Bulls Say, Bears Say
Bulls Say
Divestiture ProceedsDivestiture of the JADA System for roughly $440 million plus up to $25 million in milestone payments strengthens cash reserves and reduces exposure to non-core assets.
Leverage TargetCompany commitment to keep net debt to adjusted EBITDA below four times signals a focus on deleveraging that could improve credit perception and investor confidence.
Bears Say
Dividend Policy And SentimentA surprising dividend cut increased investor concern about cash allocation and may prolong negative sentiment absent a clear capital-allocation plan from management.
Governance And ComplianceInvestigation finding that U.S. wholesalers were encouraged to overpurchase Nexplanon, followed by the CEO resignation, raises governance and compliance concerns that could attract regulatory scrutiny and erode trust.
Revenue OutlookLowered revenue guidance driven by U.S. policy headwinds for Nexplanon and softness in the respiratory franchise highlights near-term revenue risk and may pressure growth expectations.
Organon News
OGN FAQ
What was Organon & Co.’s price range in the past 12 months?
Organon & Co. lowest stock price was $5.69 and its highest was $13.48 in the past 12 months.
What is Organon & Co.’s market cap?
Organon & Co.’s market cap is $3.53B.
When is Organon & Co.’s upcoming earnings report date?
Organon & Co.’s upcoming earnings report date is Aug 11, 2026 which is in 59 days.
How were Organon & Co.’s earnings last quarter?
Organon & Co. released its earnings results on Apr 30, 2026. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.829 by -$0.119.
Is Organon & Co. overvalued?
According to Wall Street analysts Organon & Co.’s price is currently Undervalued.
Does Organon & Co. pay dividends?
Organon & Co. pays a Quarterly dividend of $0.02 which represents an annual dividend yield of 4.8%. See more information on Organon & Co. dividends here
What is Organon & Co.’s EPS estimate?
Organon & Co.’s EPS estimate is 0.89.
How many shares outstanding does Organon & Co. have?
Organon & Co. has 262,609,440 shares outstanding.
What happened to Organon & Co.’s price movement after its last earnings report?
Organon & Co. reported an EPS of $0.71 in its last earnings report, missing expectations of $0.829. Following the earnings report the stock price went down -0.676%.
Which hedge fund is a major shareholder of Organon & Co.?
Currently, no hedge funds are holding shares in OGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.33 (26.37% Upside)
$12.33 (26.37% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $352.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.62%
12-Months-Change
Fundamentals
Return on Equity
29.87%
Trailing 12-Months
Asset Growth
-1.22%
Trailing 12-Months
Company Description
Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
OGN Company Deck
OGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: several strong, tangible positives (stable full-year guidance, robust biosimilars growth—Hadlima +61% ex-FX—Vtama/Emgality momentum, >$200M cost savings, $960M free cash flow, $390M Jada divestiture and active deleveraging). Offsetting these are meaningful near-term commercial and margin headwinds (revenue down ~3% FY, Q4 -8% CC; Nexplanon channel and policy impacts with Q4 Nexplanon -20% ex-FX; respiratory pricing pressure; gross margin deterioration and a Q4 goodwill impairment), plus some governance/uncertainty from unresolved audit matters. Management expects flat 2026 results and continued focus on cost discipline and balance sheet repair, but several execution and market risks remain.View all OGN earnings summariesOGN Stock 12 Month Forecast
Average Price Target
$12.33
▲(26.37% Upside)
Technical Analysis
Ownership Overview
0.34% Insiders
17.41% Mutual Funds
14.48% Other Institutional Investors
42.66% Public Companies and
Individual Investors